| P50 | author | Maree Smith | Q24851696 |
| | Arjun Muralidharan | Q39184346 |
| | Arjun Muralidharan | Q85074407 |
| P2860 | cites work | Radioisotopes for metastatic bone pain | Q24235589 |
| | Bisphosphonates for advanced prostate cancer | Q24244161 |
| | NSAIDS or paracetamol, alone or combined with opioids, for cancer pain | Q24246917 |
| | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Src family kinases in tumor progression and metastasis | Q24311656 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | The role of RANK-ligand inhibition in cancer: the story of denosumab | Q24633284 |
| | Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase | Q24746249 |
| | Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 |
| | Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture | Q28202184 |
| | Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells | Q28204395 |
| | Normal bone anatomy and physiology | Q28299969 |
| | Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis | Q28302443 |
| | A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors | Q28346383 |
| | Impaired nociception and pain sensation in mice lacking the capsaicin receptor | Q28511370 |
| | Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation | Q28575953 |
| | Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease | Q28618665 |
| | Cellular and Molecular Mechanisms of Pain | Q29011961 |
| | Cancer statistics, 2007 | Q29547293 |
| | Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases | Q30311918 |
| | Mechanisms of Osteoblastic Metastases: Role of Endothelin-1 | Q30311986 |
| | The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor | Q30434799 |
| | Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice | Q36791739 |
| | Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial | Q44315403 |
| | Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer | Q44634009 |
| | A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer | Q44872720 |
| | Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer | Q44918129 |
| | Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients | Q45144869 |
| | Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy | Q45161200 |
| | Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. | Q46022677 |
| | An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats | Q46152819 |
| | Nerve growth factor inhibition prevents traumatic neuroma formation in the rat. | Q46168945 |
| | Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength | Q46186977 |
| | Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. | Q46192344 |
| | Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer | Q46211584 |
| | Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. | Q46375220 |
| | Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain | Q46427425 |
| | New model for the induction of osteoblastic bone metastases in rat. | Q46470070 |
| | Treatment of bone metastases and bone pain with bisphosphonates | Q46480300 |
| | Quantitative Neuropathology of a Focal Nerve Injury Causing Hyperalgesia | Q46517514 |
| | Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases | Q46587554 |
| | Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers | Q46593222 |
| | Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model | Q46616183 |
| | Phosphorylation of sodium channel Na(v)1.8 by p38 mitogen-activated protein kinase increases current density in dorsal root ganglion neurons | Q46691815 |
| | Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. | Q46842240 |
| | Phosphorylation sites on calcium channel alpha1 and beta subunits regulate ERK-dependent modulation of neuronal N-type calcium channels | Q46889147 |
| | Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid | Q46931940 |
| | New Considerations in the Design of Clinical Trials for Bone Metastases | Q47139295 |
| | Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies | Q47232994 |
| | Enlargement of the receptive field size to low intensity mechanical stimulation in the rat spinal nerve ligation model of neuropathy | Q47237852 |
| | Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. | Q47249503 |
| | Behavioral and histological effects of endoneurial administration of nerve growth factor: possible implications in neuropathic pain | Q47611891 |
| | Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. | Q47687944 |
| | Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling | Q47871615 |
| | A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis | Q47871677 |
| | Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo | Q47895026 |
| | Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system | Q48182805 |
| | A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer | Q48456368 |
| | Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. | Q48796677 |
| | Bone stem cells | Q49968520 |
| | Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review). | Q36840688 |
| | Role of the alpha v beta 3 integrin in human melanoma cell invasion | Q36847392 |
| | New and emerging therapies for bone metastases in genitourinary cancers | Q36866291 |
| | Cancer to bone: a fatal attraction | Q36884628 |
| | Involvement of alpha(v)beta3 integrins in osteoclast function | Q36984939 |
| | The use of molecular markers of bone turnover in the management of patients with metastatic bone disease | Q36990793 |
| | Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer | Q36999566 |
| | TGF-beta and BMP7 interactions in tumour progression and bone metastasis | Q37002892 |
| | Endothelin receptor antagonists in cancer therapy | Q37024077 |
| | The bone microenvironment in metastasis; what is special about bone? | Q37028803 |
| | Current trials using bone-targeting agents in prostate cancer | Q37095852 |
| | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 |
| | Mechanisms of bone metastasis in prostate cancer: clinical implications | Q37159910 |
| | Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain | Q37177577 |
| | Central neuronal mechanisms in cancer-induced bone pain. | Q37228288 |
| | Wnt signaling and prostate cancer | Q37233002 |
| | Tumor-evoked hyperalgesia and sensitization of nociceptive dorsal horn neurons in a murine model of cancer pain | Q37239670 |
| | Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis | Q37287442 |
| | Recent evidence for activity-dependent initiation of sympathetic sprouting and neuropathic pain. | Q37310902 |
| | Profiling of dynamically changed gene expression in dorsal root ganglia post peripheral nerve injury and a critical role of injury-induced glial fibrillary acidic protein in maintenance of pain behaviors [corrected]. | Q37345895 |
| | Central sensitization: a generator of pain hypersensitivity by central neural plasticity | Q37361185 |
| | Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. | Q37367672 |
| | The molecular mechanism behind bone remodelling: a review | Q37423147 |
| | Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study | Q37502039 |
| | The critical role of the bone microenvironment in cancer metastases | Q37555284 |
| | Src kinases as therapeutic targets for cancer | Q37604891 |
| | Mechanisms of breast cancer bone metastasis | Q37652640 |
| | SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer | Q37656613 |
| | Pathogenesis of osteoblastic bone metastases from prostate cancer | Q37682761 |
| | The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? | Q37694721 |
| | Treatment of painful bone metastases | Q37710370 |
| | The role of glia and the immune system in the development and maintenance of neuropathic pain | Q37729355 |
| | Bone-marker levels in patients with prostate cancer: potential correlations with outcomes | Q37758181 |
| | Dysregulation of developmental pathways in bone metastasis | Q37772654 |
| | Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. | Q50574453 |
| | Peripheral nerve injury alters excitatory synaptic transmission in lamina II of the rat dorsal horn. | Q51306058 |
| | Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. | Q51561993 |
| | A study of early ongoing activity in dorsal horn units following sciatic nerve constriction | Q51617222 |
| | Painful bone metastases: a prospective observational cohort study. | Q52857023 |
| | International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? | Q53194165 |
| | Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. | Q53914259 |
| | Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. | Q53921000 |
| | Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect | Q58970743 |
| | Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone | Q60504419 |
| | Intravenous Injection of Leconotide, an Omega Conotoxin: Synergistic Antihyperalgesic Effects with Morphine in a Rat Model of Bone Cancer Pain | Q60605623 |
| | Sclerostin antibody treatment enhances metaphyseal bone healing in rats | Q63248242 |
| | Macrophage colony stimulating factor (M-CSF) is essential for osteoclast formation in vitro | Q70175220 |
| | An electrophysiological study of dorsal horn neurons in the spinal cord of rats with an experimental peripheral neuropathy | Q70469587 |
| | Poststimulus afterdischarges of spinal WDR and NS units in rats with chronic nerve constriction | Q71952385 |
| | Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis | Q72880158 |
| | Endothelin-1 is a potent regulator of human bone cell metabolism in vitro | Q73166864 |
| | Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain | Q73263697 |
| | Functional reorganization of sensory pathways in the rat spinal dorsal horn following peripheral nerve injury | Q73703226 |
| | The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma | Q73931802 |
| | Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases | Q73977301 |
| | Nerve growth factor modulates the activation status and fast axonal transport of ERK 1/2 in adult nociceptive neurones | Q74419227 |
| | Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer | Q77602071 |
| | Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy | Q30437441 |
| | Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation | Q30441987 |
| | Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment | Q30444637 |
| | Molecular biology of bone metastasis | Q30444749 |
| | Molecular mechanisms and treatment of bone metastasis | Q30445717 |
| | Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand | Q30670375 |
| | Radiotherapy for the palliation of painful bone metastases. | Q30868320 |
| | A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone | Q31045889 |
| | Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production | Q31805202 |
| | Bisphosphonates for the relief of pain secondary to bone metastases. | Q32139406 |
| | Organization of a unique net-like meshwork of CGRP+ sensory fibers in the mouse periosteum: implications for the generation and maintenance of bone fracture pain | Q33303298 |
| | A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases | Q33348291 |
| | A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases | Q33375859 |
| | A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies | Q33405571 |
| | Breakthrough pain in cancer patients: pathophysiology and treatment | Q33585770 |
| | The pharmacology of bisphosphonates and new insights into their mechanisms of action | Q33746152 |
| | Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons | Q33907117 |
| | Mechanism of cancer pain | Q33953901 |
| | Bone health and prostate cancer | Q33977536 |
| | Sclerostin: current knowledge and future perspectives | Q33992612 |
| | Management of painful bone metastases | Q34004523 |
| | Anti-endothelin drugs in solid tumors | Q34021011 |
| | Pain affect encoded in human anterior cingulate but not somatosensory cortex. | Q34065017 |
| | Cellular and neurochemical remodeling of the spinal cord in bone cancer pain | Q34094107 |
| | CXCL12 (SDF-1)/CXCR4 pathway in cancer | Q34116260 |
| | Bone cancer pain. | Q34120101 |
| | A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma | Q34152748 |
| | Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer | Q34161050 |
| | Metastatic bone disease: role of transcription factors and future targets | Q34217531 |
| | A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer | Q34322294 |
| | Biology of osteoclast activation in cancer | Q34324255 |
| | Malignant bone pain: pathophysiology and treatment | Q34418896 |
| | A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer | Q34433349 |
| | Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. | Q40472142 |
| | The role of thrombin in tumor cell metastasis | Q40472721 |
| | Effects of physiological concentrations of steroid hormones and interleukin-11 on basal and stimulated production of interleukin-8 by human osteoblast-like cells with different functional profiles | Q40581403 |
| | Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. | Q40591646 |
| | Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain | Q40610103 |
| | Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. | Q40742643 |
| | Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts | Q41182590 |
| | Cancer therapy using bone-seeking isotopes. | Q41205760 |
| | Characterization of a rat model of metastatic prostate cancer bone pain | Q41244868 |
| | Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation. | Q41257707 |
| | Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate | Q41304383 |
| | Electrophysiological properties of spinal wide dynamic range neurons in neuropathic pain rats following spinal nerve ligation | Q41441819 |
| | Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. | Q41469995 |
| | Osteoclasts express high levels of pp60c-src in association with intracellular membranes | Q41774224 |
| | Differential ATF3 expression in dorsal root ganglion neurons reveals the profile of primary afferents engaged by diverse noxious chemical stimuli | Q41822232 |
| | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 |
| | Use of bisphosphonates in advanced prostate cancer: Current status | Q41986952 |
| | Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. | Q42068925 |
| | p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia | Q42526677 |
| | Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. | Q42556448 |
| | The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial | Q42781348 |
| | Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases | Q43096538 |
| | Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases | Q43146234 |
| | Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption | Q43195946 |
| | Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density | Q43252754 |
| | Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. | Q43272514 |
| | Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer | Q43690869 |
| | Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice | Q43716624 |
| | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 |
| | Cathepsin K mRNA and protein expression in prostate cancer progression | Q44303172 |
| | Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. | Q37775202 |
| | Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis | Q37800534 |
| | Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis | Q37813135 |
| | Steps in prostate cancer progression that lead to bone metastasis | Q37848782 |
| | A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. | Q37985149 |
| | Novel therapies in benign and malignant bone diseases. | Q37991789 |
| | Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases | Q38004275 |
| | Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells | Q38347522 |
| | Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. | Q39180043 |
| | Time course of pain relief in patients treated with radiotherapy for cancer pain: a prospective study | Q39293967 |
| | 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma | Q39339046 |
| | Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer | Q39341850 |
| | Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer | Q39380785 |
| | Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study | Q39392355 |
| | The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study | Q39403474 |
| | Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics | Q39408230 |
| | Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. | Q39411167 |
| | Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial | Q39449208 |
| | A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. | Q39452323 |
| | A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer | Q39485688 |
| | Clinical experience with strontium-89 in prostatic and breast cancer patients | Q39493290 |
| | Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. | Q39494429 |
| | A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone | Q39513078 |
| | The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group | Q39562742 |
| | Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer | Q39676621 |
| | ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating properties | Q39744096 |
| | Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation | Q39783688 |
| | Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone | Q39918594 |
| | Differential activation of spinal cord glial cells in murine models of neuropathic and cancer pain | Q39979267 |
| | Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells | Q40020055 |
| | A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. | Q40360908 |
| | Serendipity in anticancer drug discovery | Q40368701 |
| | Roles of osteonectin in the migration of breast cancer cells into bone | Q40371223 |
| | Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions | Q40380761 |
| | Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway | Q40444119 |
| | Bone stem cells | Q77808012 |
| | Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2 | Q78710366 |
| | Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan | Q78954066 |
| | Changes in response properties of nociceptive dorsal horn neurons in a murine model of cancer pain | Q79717702 |
| | Superficial dorsal horn neuronal responses and the emergence of behavioural hyperalgesia in a rat model of cancer-induced bone pain | Q79920194 |
| | Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro | Q80052261 |
| | The pharmacologic management of cancer pain | Q80238545 |
| | Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis | Q81067700 |
| | Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia | Q81195598 |
| | Sympathetic sprouting and changes in nociceptive sensory innervation in the glabrous skin of the rat hind paw following partial peripheral nerve injury | Q82679670 |
| | Delayed reinnervation by nonpeptidergic nociceptive afferents of the glabrous skin of the rat hindpaw in a neuropathic pain model | Q82682131 |
| | [Establishment of bone metastasis model of prostate cancer in nude mice by intratibia injection of human prostate cancer cell line Du145] | Q82738956 |
| | Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria | Q82766552 |
| | Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone | Q83836228 |
| | Bone continuum of cancer | Q84358136 |
| | Growth regulatory factors and bone | Q34435604 |
| | Integrins and bone metastasis: integrating tumor cell and stromal cell interactions | Q34441622 |
| | Treatment and prevention of bone complications from prostate cancer | Q34441944 |
| | Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells | Q34460378 |
| | Bone cancer induces a unique central sensitization through synaptic changes in a wide area of the spinal cord | Q34489274 |
| | Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. | Q34549971 |
| | Clinical features of metastatic bone disease and risk of skeletal morbidity | Q34576366 |
| | Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer | Q34613941 |
| | Current aproach to cancer pain management: Availability and implications of different treatment options. | Q34779398 |
| | Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer | Q34898980 |
| | Integrin targeted therapeutics | Q34912684 |
| | Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. | Q34959208 |
| | Mechanisms of osteolytic bone metastases in breast carcinoma | Q35053951 |
| | Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. | Q35062543 |
| | Antagonism of nerve growth factor-TrkA signaling and the relief of pain | Q35064559 |
| | Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain | Q35421746 |
| | Palliation of Metastatic Bone Pain: Single Fraction versus Multifraction Radiotherapy – A Systematic Review of Randomised Trials | Q35549679 |
| | A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study | Q35576853 |
| | IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology | Q35640443 |
| | Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis | Q35679829 |
| | Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. | Q35688200 |
| | Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. | Q35753328 |
| | Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. | Q35754868 |
| | The significance of cancer cell expression of the chemokine receptor CXCR4. | Q35832343 |
| | Clinical development of anti-RANKL therapy | Q35901092 |
| | Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain | Q35984168 |
| | Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer | Q36087899 |
| | Dissociation of spinal microglia morphological activation and peripheral inflammation in inflammatory pain models | Q36380148 |
| | Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy | Q36396723 |
| | Wnt signaling and osteoblastogenesis | Q36589094 |
| | Cancer pain and its impact on diagnosis, survival and quality of life | Q36599929 |
| | A "class action" against the microenvironment: do cancer cells cooperate in metastasis? | Q36649455 |
| | Targeted and systemic radiotherapy in the treatment of bone metastasis | Q36679453 |
| | The role of tumor microenvironment in prostate cancer bone metastasis | Q36771551 |
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P921 | main subject | prostate cancer | Q181257 |
| | bone | Q265868 |
| | pain management | Q621261 |
| | bone neoplasm | Q1328805 |
| | nociceptive pain | Q2533455 |
| | prostate neoplasm | Q56014511 |
| P304 | page(s) | 339-363 | |
| P577 | publication date | 2013-08-06 | |
| P1433 | published in | Inflammopharmacology | Q15751310 |
| P1476 | title | Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments | |
| P478 | volume | 21 | |